FIELD: chemical-pharmaceutical industry; medicine.
SUBSTANCE: group of inventions relates to a pharmaceutical composition and a medicinal agent exhibiting preventive and/or therapeutic antiviral activity, and use thereof. Pharmaceutical composition contains in therapeutically effective amounts favipiravir and at least one aliphatic mono- or diaminomonocarboxylic non-proteinogenic amino acid with weight ratio of favipiravir to amino acid 1.0:0.1–1.0:1.20 respectively. Medicinal agent contains the above pharmaceutical composition and at least one pharmaceutically acceptable excipient. Also disclosed is use of said pharmaceutical composition for preparing a drug exhibiting preventive and/or therapeutic antiviral activity.
EFFECT: group of inventions provides a wider range of antiviral agents, pharmaceutical composition and medicinal agent described above have improved processing characteristics, stability and bioavailability.
52 cl, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID HYDRATE AND/OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2021 |
|
RU2789612C1 |
| METHOD OF PRODUCING NOVEL DERIVATIVES OF FAVIPIRAVIR | 2023 |
|
RU2828875C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2751108C1 |
| ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827154C1 |
| NOVEL FORMS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | 2023 |
|
RU2827157C1 |
